| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Guy Lippens, Alain Sillen, Isabelle Landrieu, Laziza Amniai, Nathalie Sibille, Pascale Barbier, Arnaud Leroy, Xavier Hanoulle, Jean-Michel Wieruszesk. Tau aggregation in Alzheimer's disease: what role for phosphorylation? Prion. vol 1. issue 1. 2009-03-18. PMID:19164903. |
tau aggregation in alzheimer's disease: what role for phosphorylation? |
2009-03-18 |
2023-08-12 |
Not clear |
| Michael S Rafii, Paul S Aise. Recent developments in Alzheimer's disease therapeutics. BMC medicine. vol 7. 2009-03-18. PMID:19228370. |
primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of alzheimer's disease, and tau protein which, when hyperphosphorylated, results in the self-assembly of tangles of paired helical filaments also believed to be involved in the pathogenesis of alzheimer's disease. |
2009-03-18 |
2023-08-12 |
human |
| Mitul Sarkar, Jeff Kuret, Gloria Le. Two motifs within the tau microtubule-binding domain mediate its association with the hsc70 molecular chaperone. Journal of neuroscience research. vol 86. issue 12. 2009-03-16. PMID:18500754. |
tau, a microtubule-associated protein with multiple phosphorylation sites, forms aggregates that correlate with neurodegeneration in alzheimer's disease and several other neurodegenerative diseases, termed tauopathies. |
2009-03-16 |
2023-08-12 |
Not clear |
| Jozef Sevcik, Rostislav Skrabana, Eva Kontsekova, Michal Nova. Structure solution of misfolded conformations adopted by intrinsically disordered Alzheimer's tau protein. Protein and peptide letters. vol 16. issue 1. 2009-03-05. PMID:19149675. |
structure solution of misfolded conformations adopted by intrinsically disordered alzheimer's tau protein. |
2009-03-05 |
2023-08-12 |
Not clear |
| Jozef Sevcik, Rostislav Skrabana, Eva Kontsekova, Michal Nova. Structure solution of misfolded conformations adopted by intrinsically disordered Alzheimer's tau protein. Protein and peptide letters. vol 16. issue 1. 2009-03-05. PMID:19149675. |
until now it was impossible to obtain atomic structure of intrinsically disordered protein (idp) tau and/or its assembly in alzheimer's paired helical filaments as neither of them could have been prepared in the form amenable to x-ray or nmr techniques. |
2009-03-05 |
2023-08-12 |
Not clear |
| Jianhua Zhou, Qingming Yu, Tie Zo. Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. BMC neuroscience. vol 9 Suppl 2. 2009-03-04. PMID:19090983. |
tau aggregation is one of the major features in alzheimer's disease and in several other tauopathies, including frontotemporal dementia with parkinsonism linked to chromosome 17 (ftdp-17), and progressive supranuclear palsy (psp). |
2009-03-04 |
2023-08-12 |
Not clear |
| Thomas Timm, Alexander Marx, Saravanan Panneerselvam, Eckhard Mandelkow, Eva-Maria Mandelko. Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein. BMC neuroscience. vol 9 Suppl 2. 2009-03-04. PMID:19090997. |
protein kinases of the mark family phosphorylate tau protein in its repeat domain and thereby regulate its affinity for microtubules and affect the aggregation of tau into alzheimer paired helical filaments. |
2009-03-04 |
2023-08-12 |
Not clear |
| Ludovic Martin, Amandine Magnaudeix, Françoise Esclaire, Catherine Yardin, Faraj Terr. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain research. vol 1252. 2009-02-27. PMID:19071093. |
in tauopathies such as alzheimer's disease (ad), the molecular mechanisms of tau protein aggregation into neurofibrillary tangles (nfts) and their contribution to neurodegeneration remain not understood. |
2009-02-27 |
2023-08-12 |
Not clear |
| Lydia Giménez-Llort, Lorena Arranz, Ianire Maté, Mónica De la Fuent. Gender-specific neuroimmunoendocrine aging in a triple-transgenic 3xTg-AD mouse model for Alzheimer's disease and its relation with longevity. Neuroimmunomodulation. vol 15. issue 4-6. 2009-02-26. PMID:19047809. |
in the present work, we briefly review the evidence on the key role played by the neuroimmunoendocrine network in the etiopathogenesis of alzheimer's disease (ad) and provide new behavioral, immune and endocrinological data obtained on old male and female triple-transgenic 3xtg-ad mice harboring ps1(m146v), app(swe) and tau(p301l) transgenes in contrast to wild-type animals. |
2009-02-26 |
2023-08-12 |
mouse |
| João P Lopes, Catarina R Oliveira, Paula Agostinh. Cdk5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-beta and prion peptides. Cell cycle (Georgetown, Tex.). vol 8. issue 1. 2009-02-25. PMID:19158499. |
involved in tau protein hyperphosphorylation and apoptotic neuronal death, two main neuropathological markers of alzheimer's disease (ad) and prion-related encephalopathies (pre), cdk5 also participates in cell cycle regulation. |
2009-02-25 |
2023-08-12 |
Not clear |
| Maria Gulinello, Michael Gertner, Guadalupe Mendoza, Brian P Schoenfeld, Salvatore Oddo, Frank LaFerla, Catherine H Choi, Sean M J McBride, Donald S Fabe. Validation of a 2-day water maze protocol in mice. Behavioural brain research. vol 196. issue 2. 2009-02-24. PMID:18831990. |
we validated this procedure using aged (15-18m) mice expressing three alzheimer's disease-related transgenes, ps1(m146 v), app(swe), and tau(p301l). |
2009-02-24 |
2023-08-12 |
mouse |
| May Gohar, Wencheng Yang, Wendy Strong, Kathryn Volkening, Cheryl Leystra-Lantz, Michael J Stron. Tau phosphorylation at threonine-175 leads to fibril formation and enhanced cell death: implications for amyotrophic lateral sclerosis with cognitive impairment. Journal of neurochemistry. vol 108. issue 3. 2009-02-24. PMID:19046355. |
both soluble and insoluble tau was purified from control, patients with alzheimer's disease (ad), als without cognitive impairment, and alsci and the tendency to fibril formation assayed ex vivo using the thioflavin s fluorescence assay. |
2009-02-24 |
2023-08-12 |
human |
| Ramasamy Thangavel, Gary W Van Hoesen, Asgar Zahee. The abnormally phosphorylated tau lesion of early Alzheimer's disease. Neurochemical research. vol 34. issue 1. 2009-02-23. PMID:18437565. |
the abnormally phosphorylated tau lesion of early alzheimer's disease. |
2009-02-23 |
2023-08-12 |
human |
| Ramasamy Thangavel, Gary W Van Hoesen, Asgar Zahee. The abnormally phosphorylated tau lesion of early Alzheimer's disease. Neurochemical research. vol 34. issue 1. 2009-02-23. PMID:18437565. |
the perirhinal cortex (area 35) is well-known locus for neurofibrillary tangles (nft) in initial alzheimer's disease (ad) and fully developed ad and may contain tau alterations in non-demented elderly. |
2009-02-23 |
2023-08-12 |
human |
| Li Liu, Karen Duf. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. Journal of visualized experiments : JoVE. issue 21. 2009-02-23. PMID:19066529. |
alzheimer's disease (ad) is a progressive neurodegenerative disease that is pathologically characterized by extracellular deposition of beta-amyloid peptide (abeta) and intraneuronal accumulation of hyperphosphorylated tau protein. |
2009-02-23 |
2023-08-12 |
mouse |
| D R Howlett, J C Richardso. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? Histology and histopathology. vol 24. issue 1. 2009-02-20. PMID:19012248. |
alzheimer's disease (ad) is characterized by a number of pathological features, notably extracellular senile plaques composed of the beta-amyloid protein (abeta) and neurofibrillary tangles (nft's), which are intracellular inclusions of hyperphosphorylated tau protein. |
2009-02-20 |
2023-08-12 |
mouse |
| Roland Brandt, Aikaterini Gergou, Irene Wacker, Thomas Fath, Harald Hutte. A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiology of aging. vol 30. issue 1. 2009-02-19. PMID:17590239. |
a caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of alzheimer's disease-like modified tau. |
2009-02-19 |
2023-08-12 |
human |
| Roland Brandt, Aikaterini Gergou, Irene Wacker, Thomas Fath, Harald Hutte. A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiology of aging. vol 30. issue 1. 2009-02-19. PMID:17590239. |
the microtubule-associated tau proteins become functionally and structurally altered in alzheimer's disease (ad). |
2009-02-19 |
2023-08-12 |
human |
| Franziska Denk, Richard Wade-Martin. Knock-out and transgenic mouse models of tauopathies. Neurobiology of aging. vol 30. issue 1. 2009-02-19. PMID:17590238. |
tauopathies, characterized by the dysfunction and aggregation of the microtubule-associated protein tau (mapt), represent some of the most devastating neurodegenerative disorders afflicting the elderly, including alzheimer's disease and progressive supranuclear palsy. |
2009-02-19 |
2023-08-12 |
mouse |
| B Borroni, F Gardoni, L Parnetti, L Magno, M Malinverno, E Saggese, P Calabresi, M G Spillantini, A Padovani, M Di Luc. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiology of aging. vol 30. issue 1. 2009-02-19. PMID:17709155. |
cerebrospinal fluid (csf) total tau levels vary widely in neurodegenerative disorders, thus being not useful in their discrimination over alzheimer disease. |
2009-02-19 |
2023-08-12 |
human |